Answers are grounded in this paper and cite their sources.
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. This post hoc analysis investigated the efficacy and safety of CAB in pediatric (<18 years) and adult (greater than or equal to 18 years) participants.
No takes yet. Share an insight, caveat, or question.
Baldwin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: